Fig. 5

SAG repressed BMECs immune reaction and neuroinflammation of infected mice in vivo and in vitro. A Western blot detecting expression of E-selectin, KRAS and ERK1/2 phosphorylation in RS218 infected hBMECs with or without SAG pre-treatment (at 10 μM). B qPCR detecting expression alterations of IL-6, MIP-2, and E-selectin in RS218 infected hBMECs with or without SAG pre-treatment (at 10 μM). **p < 0.01. The qPCR assays were performed in triplicates, and results are presented as mean ± SEM. C qPCR detecting MIR155HG, miR-155, and KRAS expression upon RS218 infection in hBMECs. The cells were pretreated with or without SAG pre-treatment (at 10 μM). *p < 0.05, **p < 0.01. The qPCR assays were performed in triplicates, and results are presented as mean ± SEM. D Effects of the SAG pre-treatment at 10 mg/kg (for 12 h) on the survival of the mice after the challenge of RS218 (n = 10). **p < 0.01. E ELISA analysis of IL-6 and MIP-2 in brain lysates from RS218 challenged mice with or without SAG pre-treatment at 10 mg/kg. Data are presented as mean ± SEM from five individual mice in each group. F IF assays showing the E-selectin and KRAS expression in brains of mice challenged by RS218 with or without SAG pre-treatment (at 10 mg/kg). The E-selection and KRAS were stained in red. CD31 was specifically applied for labeling the micro-vessels in green. The cell nucleus was stained in blue with DAPI. Scale bar = 50 μm